The IGF2BP3 Knockout A-549 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population in which the IGF2BP3 gene has been disrupted in the A-549 human lung adenocarcinoma cell line. This polyclonal model provides a heterogeneous loss-of-function system for investigating IGF2BP3-dependent cellular processes without the assumption of clonal homogeneity. By utilizing a population of edited cells, researchers can assess the collective impact of IGF2BP3 disruption on oncogenic phenotypes, capturing the diversity of genetic alterations generated by CRISPR/Cas9-mediated targeting. This product is particularly suited for applications requiring pooled knockout cells, such as pooled functional screens or bulk transcriptomic analyses, where a representative cellular population reflects the overall biological consequence of gene disruption.
A-549 cells are an adherent epithelial line originally derived from the lung adenocarcinoma of a 58-year-old male. These cells are extensively characterized and widely employed as a model for non-small cell lung cancer (NSCLC), especially lung adenocarcinoma. A-549 cells exhibit key features of malignant epithelial cells, including the ability to proliferate in vitro, migrate, and form colonies, making them a robust platform for cancer biology research. Their genetic background recapitulates many clinically relevant NSCLC alterations, and they have been instrumental in studies of oncogenic signaling, drug resistance, and metastasis. The A-549 line is a standard host for gene editing to examine molecular mechanisms underlying lung adenocarcinoma and to evaluate potential therapeutic interventions.
IGF2BP3 encodes an RNA-binding protein of the insulin-like growth factor 2 mRNA-binding protein family that specifically recognizes N6-methyladenosine (m6A)-modified mRNAs. Through its binding to m6A marks, IGF2BP3 enhances the stability and translational efficiency of target transcripts, thereby elevating protein output. This protein promotes cell proliferation, migration, and invasion, and is frequently upregulated in aggressive cancers. IGF2BP3 is transcriptionally activated by MYC and the ??-catenin/TCF complex, and its expression is modulated by NF-??B and TGF-?? signaling, while being post-transcriptionally repressed by let-7 miRNAs. It stabilizes and enhances translation of key oncogenic mRNAs including MYC, CD44, IGF1R, BCL2, and HMGA2. IGF2BP3 operates within the m6A epitranscriptomic machinery, interacting with the METTL3/METTL14 methyltransferase complex, translation initiation factor eIF4E, and the RNA-binding protein HuR (ELAVL1). Downstream, it potentiates signaling through PI3K/AKT, Wnt/??-catenin, and NF-??B cascades, thereby reinforcing proliferative and survival programs.
In the A-549 lung adenocarcinoma context, disruption of IGF2BP3 is expected to reduce the stability of its oncogenic target mRNAs, leading to decreased expression of proteins that drive cell cycle progression, inhibit apoptosis, and promote motility. This polyclonal knockout model enables the study of how loss of IGF2BP3 affects tumorigenic properties such as anchorage-independent growth, migratory capacity, and resistance to chemotherapeutics. Given A-549 cells’ relevance to NSCLC, the model is particularly suited to interrogate the role of m6A-dependent regulation in lung adenocarcinoma progression, including the contribution of downstream effectors like LEF1 and HMGA2 to epithelial-mesenchymal transition and metastasis. The heterogeneous knockout population mirrors the natural variation found in tumor cell populations, potentially revealing subtle phenotypes that might be masked in clonal lines.
This IGF2BP3 polyclonal knockout model is ideal for a range of research applications, including transcriptome-wide identification of mRNA targets via RNA-seq, m6A-RIP-seq for mapping m6A-modified RNAs, and functional assays such as MTT cell proliferation, Transwell migration and invasion, colony formation, and flow cytometric analysis of apoptosis using Annexin V staining. It can be employed in xenograft tumor growth studies to evaluate in vivo tumorigenicity and to screen for small molecules that selectively inhibit IGF2BP3-driven pathways. The model also facilitates investigation of drug resistance mechanisms and the interplay between m6A modifications and oncogenic signaling. For additional information or customized applications, please contact Ascent Research.
